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Microscopy of Cryptococcus neoformans.
Cryptococcal Infection
What is Cryptococcus?
Cryptococcus is a fungus that is found in the soil throughout the world. Because  
Cryptococcus is common in the environment, most people probably breathe in  
small amounts of microscopic, airborne spores every day. Sometimes these 
spores cause symptoms of a respiratory infection, but other times there are no  
symptoms at all. In healthy people, the fungus usually does not cause serious  
illness because the immune system can fight off the infection. However, in  
people with weakened immune systems, such as people with HIV/AIDS, the fungus 
can stay hidden in the body and later reactivate, spreading to other parts of the body  
and causing serious disease. 
Cryptococcal meningitis
An infection with the fungus Cryptococcus is known as cryptococcosis, and it is a serious  
opportunistic infection among people with advanced HIV/AIDS. Cryptococcosis is not 
contagious, meaning it cannot spread from person-to-person. Cryptococcal meningitis 
specifically occurs after Cryptococcus has spread from the lungs to the brain. Meningitis can  
also be caused by a variety of other organisms, including bacteria, viruses, and other fungi. 
Symptoms of meningitis include:
 • Headache
 • Fever
 • Neck pain
 • Nausea and vomiting
 • Sensitivity to light
 • Altered mental status  
(ranging from confusion to coma)
A global problem
Worldwide, approximately 1 million  
new cases of cryptococcal meningitis  
occur each year, resulting in 625,000  
deaths. Most cases are opportunistic 
infections that occur among people with  
HIV/AIDS. Although the widespread  
availability of antiretroviral therapy (ART)  
in developed countries has helped reduce  
cryptococcal infections in these areas, it is  
still a major problem in developing  
countries where access to healthcare is  
limited. Throughout much of sub-Saharan  
Africa, for example, Cryptococcus is now the 
most common cause of adult meningitis.  
Cryptococcal meningitis is one of the  
leading causes of death in HIV/AIDS  
patients; in sub-Saharan Africa, it may kill  
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Preventing Deaths Due to Cryptococcus
Targeted screening: a cost-effective strategy
One approach to prevent deaths is known as “targeted screening.” Cryptococcal antigen, a 
chemical marker for infection, can be present and detected in the body weeks to months 
before the onset of symptoms. In a targeted screening program, HIV-infected patients 
are tested for cryptococcal antigen before starting ART. A patient who tests positive for 
cryptococcal antigen can take oral fluconazole to help the body fight the early stage of the 
infection. This could prevent the infection from developing into meningitis. 
A simple new test for Cryptococcus
A new “dipstick” test for detecting cryptococcal antigen is simple to use 
on a small sample of serum (a component of blood). The test accurately 
detects both early and advanced cryptococcal infections more than 
95% of the time. In addition, the test is inexpensive, and the results are 
ready in just 10 minutes. 
Access to essential care
In order to screen patients for cryptococcal disease, as well as diagnose other patients with 
cryptococcal meningitis, healthcare facilities must have access to diagnostic tests. Currently, 
these tests are unavailable in most district and provincial laboratories in sub-Saharan Africa. 
Equipping these facilities with the ability to perform the new dipstick test is an important step 
in combating cryptococcal meningitis.
Essential medications for the treatment of cryptococcal disease are also lacking in areas of the 
world that are most in need. Amphotericin B and flucytosine, antifungal medications that have 
been shown to improve survival in patients with advanced disease and are the standard-of-care 
in developed countries, are widely unavailable in sub-Saharan Africa. 
Integration with HIV/AIDS care and treatment
Like co-trimoxazole prophylaxis and isoniazid preventive therapy (IPT), cryptococcal screening 
and treatment of antigenemia with oral fluconazole can be part of an integrated care and 
treatment strategy for people living with HIV/AIDS. In areas where cryptococcal disease 
prevalence is high, an integrated approach can help reduce early mortality among HIV/AIDS 
patients starting ART.
CDC’s response
CDC is focusing its efforts on countries in sub-Saharan Africa and Southeast Asia, the areas with the 
highest number of deaths due to cryptococcal disease. In these regions, CDC is helping build laboratory 
capacity to reliably diagnose cryptococcal infections and is assisting with the implementation of targeted 
cryptococcal screening programs. In the future, it is hopeful that diagnostic tests will be available even in 
remote, rural areas. 
CDC’s call to action is to equip half of all HIV clinics in Africa and Asia in areas with a high prevalence of 
HIV/AIDS to perform cryptococcal screening and treatment, which could save 50,000 to 100,000 lives every 
year. Early identification of cryptococcal-infected patients in resource-limited settings may lead to more 
timely treatment, reduced mortality due to cryptococcal meningitis, and overall improved quality of life.
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What You Can Do
Physicians and other healthcare providers can:
 • Familiarize themselves with the World Health Organization’s most up-
to-date guidelines on the diagnosis, prevention, and management of 
cryptococcal disease in HIV-infected individuals, available on the web at: 
http://whqlibdoc.who.int/publications/2011/9789241502979_eng.pdf
 • Be aware of the benefits of targeted screening for cryptococcal 
antigenemia among patients at risk
 • Advocate to implement cryptococcal screening programs at clinics where 
the prevalence of HIV/AIDS is high
 • Teach at-risk patients about Cryptococcus and the importance of screening 
for cryptococcal antigenemia
 • Advocate for cryptococcal diagnostic capabilities and increased 
availability of antifungal treatment in resource-limited settings
 • Visit http://preventcrypto.org/ to learn more about how to prevent deaths 
due to Cryptococcus
Non-governmental organizations (NGOs) can:
 • Partner with healthcare facilities to consider implementing targeted 
cryptococcal screening programs in areas of the world where the 
prevalence of HIV/AIDS is high
 • Get involved with monitoring and evaluation of existing cryptococcal 
screening programs
 • Advocate for cryptococcal diagnostic capabilities and increased 
availability of antifungal treatment in resource-limited settings
Government organizations can:
 • Create policies that support the development of sustainable cryptococcal 
screening programs
 • Ensure cryptococcal diagnostic capabilities and adequate access to 
antifungal medications 
 • Develop national guidelines for the diagnosis, management, and 
prevention of cryptococcal disease which are consistent with the World 
Health Organization’s recommendations
For more information, please contact the 
Centers for Disease Control and Prevention (CDC), National Center for Emerging and Zoonotic Infectious Diseases
Division of Foodborne, Waterborne, and Environmental Diseases
1600 Clifton Road, NE, Mail Stop C-09, Atlanta, GA  30329-4018
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